We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
+$158M
Cap. Flow
+$341M
Cap. Flow %
22.28%
Top 10 Hldgs %
52.34%
Holding
81
New
20
Increased
20
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$69.5M
2
MDT icon
Medtronic
MDT
+$50.4M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$33.1M
4
LLY icon
Eli Lilly
LLY
+$32M
5
PTCT icon
PTC Therapeutics
PTCT
+$28.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$63.9M
2
AZN icon
AstraZeneca
AZN
+$42.7M
3
GILD icon
Gilead Sciences
GILD
+$36.7M
4
AXSM icon
Axsome Therapeutics
AXSM
+$36M
5
BSX icon
Boston Scientific
BSX
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 86.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$219M 14.32%
1,550,280
– –
SYK icon
2
Stryker
SYK
$127B
$111M 7.26%
298,567
+182,562
+157% +$69.5M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$455B
$82.1M 5.36%
+175,000
New +$88.9M
IWM icon
4
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$69.8M 4.56%
+350,000
New +$75.9M
VERA icon
5
Vera Therapeutics
VERA
$2.54B
$67.1M 4.38%
2,793,987
– –
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$15.9B
$63.3M 4.14%
510,050
+5,857
+1% +$764K
MDT icon
7
Medtronic
MDT
$107B
$50.6M 3.3%
+562,992
New +$50.4M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$36.3B
$47.6M 3.11%
176,181
+66,024
+60% +$17M
GILD icon
9
Gilead Sciences
GILD
$161B
$46.9M 3.07%
418,900
-355,327
-46% -$36.7M
LLY icon
10
Eli Lilly
LLY
$1.07T
$43.6M 2.85%
52,800
+38,436
+268% +$32M
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.41B
$43M 2.81%
2,622,192
+1,553,102
+145% +$33.1M
SLNO
12
PUT
DELISTED
Soleno Therapeutics
SLNO
$37.8M 2.47%
+529,300
New +$25.8M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$34.6M 2.26%
484,471
-272,777
-36% -$13.3M
AVBP icon
14
ArriVent BioPharma
AVBP
$1.48B
$31.4M 2.05%
1,696,752
– –
PTCT icon
15
PTC Therapeutics
PTCT
$6.37B
$29.5M 1.93%
+579,339
New +$28.9M
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.84B
$28M 1.83%
2,275,223
+1,616,596
+245% +$22.8M
DXCM icon
17
DexCom
DXCM
$27.6B
$27M 1.77%
395,975
+105,765
+36% +$8.63M
BBIO icon
18
BridgeBio Pharma
BBIO
$16.5B
$25.4M 1.66%
+734,227
New +$24.8M
REPL icon
19
Replimune Group
REPL
$814M
$24.2M 1.58%
2,479,939
-669,583
-21% -$8.29M
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7B
$23.7M 1.55%
446,839
+49,411
+12% +$2.74M
INSM icon
21
Insmed
INSM
$23.2B
$23.2M 1.52%
304,254
+47,973
+19% +$3.67M
BPMC
22
DELISTED
Blueprint Medicines
BPMC
$23.1M 1.51%
+261,039
New +$25.5M
BMY icon
23
Bristol-Myers Squibb
BMY
$127B
$22.7M 1.48%
+371,497
New +$21.7M
INCY icon
24
Incyte
INCY
$23.5B
$21.7M 1.42%
357,800
-166,467
-32% -$11.6M
ANAB icon
25
AnaptysBio
ANAB
$1.6B
$21.6M 1.41%
1,160,033
+1,027,106
+773% +$17.1M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Sofinnova Investments held 81 positions worth $1.53B, up 12% from $1.37B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Sofinnova Investments deployed $341M of net new capital in Q1 2025, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Medtronic: 562,992 shares worth $50.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $36.7M trimmed.

  • Sofinnova Investments's largest Q1 2025 buy was Medtronic: 562,992 shares worth $50.6M.
  • Sofinnova Investments added most to Stryker in Q1 2025, an estimated $69.5M increase.
  • Sofinnova Investments's biggest Q1 2025 reduction was Gilead Sciences, cutting an estimated $36.7M.
  • Sofinnova Investments fully exited AbbVie in Q1 2025, selling an estimated $63.9M.
  • Sofinnova Investments's ten largest holdings make up 52% of its $1.53B portfolio in Q1 2025.
  • Sofinnova Investments opened 20 new positions and closed 17 in Q1 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.